Global Addison's Disease Treatment Market Growth (Status and Outlook) 2025-2031

According to this study, the global Addison's Disease Treatment market size will reach US$ 1675 million by 2031.

Addison"s disease, also known as primary adrenal insufficiency and hypocortisolism, is a long-term endocrine disorder in which the adrenal glands do not produce enough steroid hormones. Symptoms generally come on slowly and may include abdominal pain, weakness, and weight loss. Darkening of the skin in certain areas may also occur. Under certain circumstances, an adrenal crisis may occur with low blood pressure, vomiting, lower back pain, and loss of consciousness. An adrenal crisis can be triggered by stress, such as from an injury, surgery, or infection.

United States market for Addison's Disease Treatment is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Addison's Disease Treatment is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Addison's Disease Treatment is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Addison's Disease Treatment players cover Pfizer, GlaxoSmithKline, Takeda, Abbott Laboratories, Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Addison's Disease Treatment Industry Forecast” looks at past sales and reviews total world Addison's Disease Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Addison's Disease Treatment sales for 2025 through 2031. With Addison's Disease Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Addison's Disease Treatment industry.

This Insight Report provides a comprehensive analysis of the global Addison's Disease Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Addison's Disease Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Addison's Disease Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Addison's Disease Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Addison's Disease Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Addison's Disease Treatment market by product type, application, key players and key regions and countries.

Segmentation by Type:
Oral Corticosteroid
Corticosteroid Injections

Segmentation by Application:
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
GlaxoSmithKline
Takeda
Abbott Laboratories
Merck
Boehringer Ingelheim
Amgen
Lupin Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver. Show more